Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
- ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I)
- Associated Disease
- acute lymphoblastic leukemia
- Source Database
- CIViC Evidence
- Description
- In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with T315I, 0/5 had MaHRs and 0/5 had MCyRs which were lower than response rates among wild type patients.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/4376
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Acute Lymphoblastic Leukemia
- Evidence Direction
- Supports
- Drug
- Dasatinib
- Evidence Level
- C
- Clinical Significance
- Resistance
- Pubmed
- 17264298
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Dasatinib | Resitance or Non-Reponse | true |